Back to Results

Revvity Inc (RVTY)

Featured in High-Beta Stocks

Revvity, Inc. is a healthcare company listed on the New York Stock Exchange under the ticker RVTY. The company provides health sciences solutions, technologies, and services across diagnostics, life sciences research, and related applications. Its portfolio includes instruments, reagents, software, subscriptions, detection and imaging technologies, warranties, training, and other services. Revvity also supplies products used in early detection and screening for conditions such as pregnancy, infectious diseases, and a range of genetic, metabolic, and developmental disorders. In addition, the company develops technologies that support genomic workflows and applications in oncology, immunodiagnostics, and drug discovery. Headquartered in Waltham, Massachusetts, Revvity was founded in 1937 and operated previously under the name PerkinElmer, Inc. until its name change in April 2023.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-RVTY
$101.65
-7.7% Downside
Fair
$117.13
6.3% Upside
Fair
Good
July 17, 2026
August 7, 2026
0.28
0.3%
August 4, 2026
51.7x
1.7x
4.3x
11.874 B
14.842 B
22.0%
91.6%
6.0
13.4%
206.1%
Valuation • Fair Value

Revvity Inc (NYSE-RVTY) Fair Value by Valuation Model

Compare the primary fair value estimate for Revvity Inc (NYSE-RVTY) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$101.65

Estimated downside of 7.7% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$102.36

Discounted cash flow valuation reference.

Ben Graham Formula Value

$23.78

Classic Ben Graham valuation formula reference.

DDM Fair Value

$77.86

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$108.88

Comparable-company valuation reference.

Analyst Price Target

$117.13

Analysts imply upside of 6.3%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Revvity Inc (NYSE-RVTY) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Revvity Inc (NYSE-RVTY)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

2.902 B

Current operating scale indicator.

Revenue Forecast

2.827 B

Forward revenue estimate.

EBITDA

855.2 M

Current operating profitability reference.

EBITDA Forecast

889.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Revvity Inc (NYSE-RVTY) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Revvity Inc (NYSE-RVTY)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

5

Mid-range quality score.

Beneish M-Score

-2.53

No elevated caution signal from this screen.

Altman Z-Score

6.0

Relatively strong balance-sheet zone.

FCF / Net Income

206.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Revvity Inc (NYSE-RVTY). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Revvity Inc (NYSE-RVTY)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 4, 2026

Days to Earnings

14

Dividend Payment Date

August 7, 2026

Ex-Dividend Date

July 17, 2026

Dividend Yield

0.3%

Income yield reference.

Upcoming Dividend

0.28

Upcoming distribution amount.

Payment Type

Cash

Distribution type as reported in the data.

Dividend Currency

USD

Currency used for the distribution.

Payout Ratio

13.4%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Revvity Inc (NYSE-RVTY), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Revvity Inc (NYSE-RVTY) Stock Forecast & Technical Outlook

Review Revvity Inc (NYSE-RVTY) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Revvity Inc (NYSE-RVTY) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Revvity Inc (NYSE-RVTY) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Revvity Inc (NYSE-RVTY) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Revvity Inc (NYSE-RVTY) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Revvity Inc (NYSE-RVTY) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Revvity Inc (NYSE-RVTY)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Revvity Inc (NYSE-RVTY) has a Hold consensus, with 6 buy, 11 hold and 0 sell recommendations in the current data set.

Buy 6
Hold 11
Sell 0
FAQ • Fast Investor Answers

Revvity Inc (NYSE-RVTY) Stock FAQ

Quick answers about Revvity Inc (NYSE-RVTY) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$101.65
Estimated downside 7.7%
Valuation Rating
Overvalued
Estimated downside of 7.7%
Analyst Target
$117.13
Implied upside 6.3%
Financial Health
Good
Current financial-health read

The current fair value estimate for Revvity Inc (NYSE-RVTY) is $101.65. This implies an estimated downside of 7.7% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 7.7% versus the current market price.

The available analyst price target for Revvity Inc (NYSE-RVTY) is $117.13. The analyst target implies estimated upside of 6.3%.

The current financial health read for Revvity Inc (NYSE-RVTY) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Revvity Inc (NYSE-RVTY) is August 4, 2026.

Based on the current data, dividend yield is 0.3%, upcoming dividend amount is 0.28, ex-dividend date is July 17, 2026, payment date is August 7, 2026.

The current P/E ratio listed for Revvity Inc (NYSE-RVTY) is 51.7x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Revvity Inc is 11.874 B.

The current enterprise value listed for Revvity Inc is 14.842 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Revvity Inc is NYSE-RVTY, and the stock is listed on NYSE.

Revvity Inc (NYSE-RVTY) is listed on NYSE.

The current debt-to-total-capital ratio listed for Revvity Inc is 22.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Revvity Inc is 91.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NYSE View more

Thermo Fisher Scientific Inc (TMO) Thermo Fisher Scientific Inc (TMO)
Danaher Corporation (DHR) Danaher Corporation (DHR)
Agilent Technologies Inc (A) Agilent Technologies Inc (A)
Waters Corporation (WAT) Waters Corporation (WAT)
IQVIA Holdings Inc (IQV) IQVIA Holdings Inc (IQV)
Mettler-Toledo International Inc (MTD) Mettler-Toledo International Inc (MTD)
West Pharmaceutical Services Inc (WST) West Pharmaceutical Services Inc (WST)
Charles River Laboratories (CRL) Charles River Laboratories (CRL)
Qiagen NV (QGEN) Qiagen NV (QGEN)
Bio-Rad Laboratories B (BIOb) Bio-Rad Laboratories B (BIOb)
Bio-Rad Laboratories Inc (BIO) Bio-Rad Laboratories Inc (BIO)
Avantor Inc (AVTR) Avantor Inc (AVTR)
Stevanato Group SpA (STVN) Stevanato Group SpA (STVN)
Ginkgo Bioworks Holdings (DNA) Ginkgo Bioworks Holdings (DNA)